Journal
CANCER
Volume 115, Issue 18, Pages 4090-4095Publisher
WILEY
DOI: 10.1002/cncr.24467
Keywords
cisplatin; sorafenib; tyrosine kinase inhibitors; urothelial cancer
Categories
Funding
- Public Health Service [CA23318, CA66636, CA21115, CA49957, CA21076]
- National Cancer Institute, National Institutes of Health
- Department of Health and Human Services
Ask authors/readers for more resources
BACKGROUND: There is no effective second-line systemic chemotherapy for patients with disease progression after cisplatin-based chemotherapy. A phase 2 trial of sorafenib was performed to determine the activity and toxicity of this agent in a multi-institutional setting in patients previously treated with 1 prior chemotherapy regimen. METHODS: Twenty-seven patients with advanced urothelial carcinoma were treated with sorafenib 400 mg orally twice daily continuously until progression or unacceptable toxicity. RESULTS: There were no objective responses observed. The 4-month progression-free survival (PFS) rate was 9.5%; median overall survival of the group was 6.8 months. There were no therapy-related deaths, and common grade 3 toxicities included fatigue and hand-foot syndrome. CONCLUSIONS: Although sorafenib as a single agent has minimal activity in patients with advanced urothelial cancer in the second-line setting, further investigation of tyrosine kinase inhibitors using different trial designs with PFS endpoints is warranted. Cancer 2009;115:4090-5. (C) 2009 American Cancer Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available